Advanced functional oculofacial indications of botulinum toxin

International Ophthalmology Clinics

Volumn 45, Issue 3, 2005, Pages 77-91

  Lee, Christina ^a   Kikkawa, Don O ^a   Pasco, Nonette Y ^a   Granet, David B ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ADRENALIN; BOTULINUM TOXIN A; CYTOKINE; EMLA; GROWTH FACTOR; LIDOCAINE; THYROID HORMONE;

APRAXIA; BLEEDING; BLEPHAROSPASM; CONJUNCTIVITIS; DECOMPRESSION SURGERY; DIPLOPIA; DRY EYE; DYSTONIA; ELECTROMYOGRAPHY; ENTROPION; EYE MOVEMENT DISORDER; EYELID RETRACTION; FACE; FACIAL NERVE PARALYSIS; FIBROSIS; HUMAN; KERATITIS; LACRIMATION; NYSTAGMUS; PAIN; PRIORITY JOURNAL; PTOSIS; RETINA DETACHMENT SURGERY; REVIEW; STRABISMUS; SYNKINESIS; TARSORRHAPHY; THYROID DISEASE; TREATMENT INDICATION; WOUND HEALING;

BOTULINUM TOXIN TYPE A; EYE DISEASES; FACIAL PARALYSIS; HUMANS; NEUROMUSCULAR AGENTS; SYNKINESIS;

EID: 22544452441     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.iio.0000167165.25649.e7     Document Type: Review

References (91)

1. Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol. 1973;12:924-927.
2. Tang-Liu DD, Aoki KR, Dolly JO, et al. Intramuscular injection of 1251-botulinum neurotoxin-complex versus 1251-botulinum-free neurotoxin: time course of tissue distribution. Toxicon. 2003;42:461-469.
3. Saks ND, Burnstine MA, Putterman AM. Glabellar rhytids in thyroid-associated orbitopathy. Ophthal Plast Reconstr Surg. 2001;17:91-95.
4. Olver JM. Botulinum toxin A treatment of overactive corrugator supercilii in thyroid eye disease. Br J Ophthalmol. 1998;82:528-533.
5. Chuenkongkaew W. Botulinum toxin treatment for upper lid retraction of dysthyroidism. J Med Assoc Thai. 2003;86:1051-1054.
6. Ozkan SB, Can D, Soylev MF, et al. Chemodenervation in treatment of upper eyelid retraction. Ophthalmologica. 1997;211:387-390.
7. Scott AB. Injection treatment of endocrine orbital myopathy. Doc Ophthalmol. 1984;58: 141-145.
8. Traisk F, Tallstedt L. Thyroid associated ophthalmopathy: botulinum toxin A in the treatment of upper eyelid retraction a pilot study. Acta Ophthalmol Scand. 2001;79: 585-588.
9. Biglan AW. Control of eyelid retraction associated with Graves' disease with botulinum A toxin. Ophthalmic Surg. 1994;25:186-188.
10. Ebner R. Botulinum toxin type A in upper lid retraction of Graves' ophthalmopathy. J Clin Neuroophthalmol. 1993;13:258-261.
11. Uddin JM, Davies PD. Treatment of upper eyelid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection. Ophthalmology. 2002;109: 1183-1187.
12. Lyons CJ, Vickers SF, Lee JP. Botulinum toxin therapy in dysthyroid strabismus. Eye. 1990;4:538-542.
13. Gair EJ, Lee JP, Khoo BK, et al. What is the role of botulinum toxin in the treatment of dysthyroid strabismus? J AAPOS. 1999;3:272-274.
14. Osako M, Keltner JL. Botulinum A toxin (Oculinum) in ophthalmology. Surv Ophthalmol. 1991;36:28-46.
15. Muhlbauer W, Holm C. Eyebrow asymmetry: ways of correction. Aesthetic Plast Surg. 1998;22:366-371.
16. Bentley C. Botulinum neurotoxin A in ophthalmology. Ophthalmic Physiol Opt. 1996; 16(Suppl 1):S9-S14.
17. Sadiq SA, Downes RN. A clinical algorithm for the management of facial nerve palsy from an oculoplastic perspective. Eye. 1998;12:219-223.
18. Smyth AG. Protective ptosis after parotid surgery induced with botulinum toxin. Br J Oral Maxillofac Surg. 1995;33:107-109.
19. Smet-Dieleman H, Van de Heyning PH, Tassignon MJ. Botulinum A toxin injection in patients with facial nerve palsy. Acta Otorhinolaryngol Belg. 1993;47:359-363.
20. Adams GG, Kirkness CM, Lee JP. Botulinum toxin A induced protective ptosis. Eye. 1987;1:603-608.
21. Kirkness CM, Adams GG, Dilly PN, et al. Botulinum toxin A-induced protective ptosis in corneal disease. Ophthalmology. 1988;95:473-480.
22. Ellis MF, Daniell M. An evaluation of the safety and efficacy of botulinum toxin type A (BOTOX) when used to produce a protective ptosis. Clin Exp Ophthalmol. 2001;29: 394-399.
23. Wuebbolt GE, Drummond G. Temporary tarsorrhaphy induced with type A botulinum toxin. Can J Ophthalmol. 1991;26:383-385.
24. Heyworth PL, Lee JP. Persisting hypotropias following protective ptosis induced by botulinum neurotoxin. Eye. 1994;8:511-515.
25. Vissenberg I, Dieleman-Smet H, Tassignon MJ. Botulinum A toxin therapy in ophthalmology: a report of patients with facial dystonias. Bull Soc Belge Ophtalmol. 1993;248:77-82.
26. Tozlovanu V, Forget R, Iancu A, et al. Prolonged orbicularis oculi activity: a major factor in apraxia of lid opening. Neurology. 2001;57:1013-1018.
27. Krack P, Marion MH. "Apraxia of lid opening," a focal eyelid dystonia: clinical study of 32 patients. Mov Disord. 1994;9:610-615.
28. Lepore V, Defazio G, Acquistapace D, et al. Botulinum A toxin for the so-called apraxia of lid opening. Mov Disord. 1995;10:525-526.
29. Forget R, Tozlovanu V, Iancu A, et al. Botulinum toxin improves lid opening delays in blepharospasm-associated apraxia of lid opening. Neurology. 2002;58:1843-1846.
30. Piccione F, Mancini E, Tonin P, et al. Botulinum toxin treatment of apraxia of eyelid opening in progressive supranuclear palsy: report of two cases. Arch Phys Med Rehabil. 1997;78:525-529.
31. Borodic GE, Cozzolino D, Ferrante R, et al. Innervation zone of orbicularis oculi muscle and implications for botulinum A toxin therapy. Ophthal Plast Reconstr Surg. 1991;7:54-60.
32. Soylev MF, Kocak N, Kuvaki B, et al. Anesthesia with EMLA cream for botulinum A toxin injection into eyelids. Ophthalmologica. 2002;216:355-358.
33. Linder JS, Edmonson BC, Laquis SJ, et al. Skin cooling before periocular botulinum toxin A injection. Ophthal Plast Reconstr Surg. 2002;18:441-442.
34. Clarke JR, Spalton DJ. Treatment of senile entropion with botulinum toxin. Br J Ophthalmol. 1988;72:361-362.
35. Dalgleish R, Smith JL. Mechanics and histology of senile entropion. Br J Ophthalmol. 1966;50:79-91.
36. Botulinum toxin therapy of eye muscle disorders. Safety and effectiveness. American Academy of Ophthalmology. Ophthalmology. 1989;2:37-41.
37. Carruthers JD. Ophthalmologic use of botulinum A exotoxin. Can J Ophthalmol. 1985; 20:135-141.
38. Steel DH, Hoh HB, Harrad RA, et al. Botulinum toxin for the temporary treatment of involutional lower lid entropion: a clinical and morphological study. Eye. 1997;11: 472-475.
39. Neetens A, Rubbens MC, Smet H. Botulinum A-toxin treatment of spasmodic entropion of the lower eyelid. Bull Soc Belge Ophtalmol. 1987;224:105-109.
40. Carruthers J, Stubbs HA. Botulinum toxin for benign essential blepharospasm, hemifacial spasm and age-related lower eyelid entropion. Can J Neurol Sci. 1987;14: 42-45.
41. Putterman AM. Botulinum toxin injections in the treatment of seventh nerve misdirection. Am J Ophthalmol. 1990;110:205-206.
42. Armstrong MW, Mountain RE, Murray JA. Treatment of facial synkinesis and facial asymmetry with botulinum toxin type A following facial nerve palsy. Clin Otolaryngol. 1996;21:15-20.
43. Boroojerdi B, Ferbert A, Schwarz M, et al. Botulinum toxin treatment of synkinesia and hyperlacrimation after facial palsy. J Neurol Neurosurg Psychiatry. 1998;65:111-114.
44. Ramsay J, Taylor D. Congenital crocodile tears: a key to the aetiology of Duane's syndrome. Br J Ophthalmol. 1980;64:518-522.
45. Marsh IB. Botulinum toxin and the eye. Hosp Med. 2003;64:464-467.
46. Yavuzer R, Basterzi Y, Akata F. Botulinum toxin A for the treatment of crocodile tears. Plast Reconstr Surg. 2002;110:369-370.
47. Keegan DJ, Geerling G, Lee JP, et al. Botulinum toxin treatment for hyperlacrimation secondary to aberrant regenerated seventh nerve palsy or salivary gland transplantation. Br J Ophthalmol. 2002;86:43-46.
48. Montoya FJ, Riddell CE, Caesar R, et al. Treatment of gustatory hyperlacrimation (crocodile tears) with injection of botulinum toxin into the lacrimal gland. Eye. 2002; 16:705-709.
49. Riemann R, Pfennigsdorf S, Riemann E, et al. Successful treatment of crocodile tears by injection of botulinum toxin into the lacrimal gland: a case report. Ophthalmology. 1999;106:2322-2324.
50. Baranano DE, Miller NR. Long term efficacy and safety of botulinum toxin A injection for crocodile tears syndrome. Br J Ophthalmol. 2004;88:588-589.
51. Hofmann RJ. Treatment of Frey's syndrome (gustatory sweating) and "crocodile tears" (gustatory epiphora) with purified botulinum toxin. Ophthal Plast Reconstr Surg. 2000; 16:289-291.
52. Spiera H, Asbell PA, Simpson DM. Botulinum toxin increases tearing in patients with Sjogren's syndrome: a preliminary report. J Rheumatol. 1997;24:1842-1843.
53. Sahlin S, Chen E, Kaugesaar T, et al. Effect of eyelid botulinum toxin injection on lacrimal drainage. Am J Ophthalmol. 2000;129:481-486.
54. Gassner HG, Sherris DA, Otley CC. Treatment of facial wounds with botulinum toxin A improves cosmetic outcome in primates. Plast Reconstr Surg. 2000;105:1948-1955.
55. Sherris DA, Gassner HG. Botulinum toxin to minimize facial scarring. Facial Plast Surg. 2002;18:35-39.
56. Choi JC, Lucarelli MJ, Shore JW. Use of botulinum A toxin in patients at risk of wound complications following eyelid reconstruction. Ophthal Plast Reconstr Surg. 1997;13: 259-264.
57. Leigh RJ, Tomsak RL, Grant MP, et al. Effectiveness of botulinum toxin administered to abolish acquired nystagmus. Ann Neurol. 1992;32:633-642.
58. Menon GJ, Thaller VT. Therapeutic external ophthalmoplegia with bilateral retrobulbar botulinum toxin-an effective treatment for acquired nystagmus with oscillopsia. Eye. 2002;16:804-806.
59. Ruben ST, Lee JP, O'Neil D, et al. The use of botulinum toxin for treatment of acquired nystagmus and oscillopsia. Ophthalmology. 1994;101:783-787.
60. Helveston EM, Pogrebniak AE. Treatment of acquired nystagmus with botulinum A toxin. Am J Ophthalmol 1988;106:584-586.
61. Repka MX, Savino PJ, Reinecke RD. Treatment of acquired nystagmus with botulinum neurotoxin A. Arch Ophthalmol. 1994;112:1320-1324.
62. Thomas R, Mathai A, Braganza A, et al. Periodic alternating nystagmus treated with retrobulbar botulinum toxin and large horizontal muscle recession. Indian J Ophthalmol. 1996;44:170-172.
63. Lennerstrand G, Nordbo OA, Tian S, et al. Treatment of strabismus and nystagmus with botulinum toxin type A. An evaluation of effects and complications. Acta Ophthalmol Scand. 1998;76:27.
64. Tomsak RL, Remler BF, Averbuch-Heller L, et al. Unsatisfactory treatment of acquired nystagmus with retrobulbar injection of botulinum toxin. Am J Ophthalmol. 1995;119: 489-496.
65. Stahl JS, Plant GT, Leigh RJ. Medical treatment of nystagmus and its visual consequences. J R Soc Med. 2002;95:235-237.
66. Carruthers J. The treatment of congenital nystagmus with Botox. J Pediatr Ophthalmol Strabismus. 1995;32:306-308.
67. Oculinum: an ocular therapeutic use for a notorious toxin. Aust N Z J Ophthalmol. 1986; 14:87-88.
68. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 1980;87:1044-1049.
69. Benabent EC, Garcia Hermosa P, Arrazola MT, et al. Botulinum toxin injection without electromyographic assistance. J Pediatr Ophthalmol Strabismus. 2002;39:231-234.
70. McNeer KW, Spencer RF, Tucker MG. Observations on bilateral simultaneous botulinum toxin injection in infantile esotropia. J Pediatr Ophthalmol Strabismus. 1994; 31:214-219.
71. Campos EC, Schiavi C, Bellusci C. Critical age of botulinum toxin treatment in essential infantile esotropia. J Pediatr Ophthalmol Strabismus. 2000;37:328-332; quiz 354-355.
72. Scott AB, Magoon EH, McNeer KW, et al. Botulinum treatment of childhood strabismus. Ophthalmology. 1990;97:1434-1438.
73. McNeer KW, Tucker MG, Spencer RF. Botulinum toxin therapy for essential infantile esotropia in children. Arch Ophthalmol. 1998;116:701-703.
74. Rayner SA, Hollick EJ, Lee JP. Botulinum toxin in childhood strabismus. Strabismus. 1999;7:103-111.
75. Magoon EH. Chemodenervation of strabismic children. A 2- to 5-year follow-up study compared with shorter follow-up. Ophthalmology. 1989;96:931-934.
76. McNeer KW, Tucker MG, Guerry CH, et al. Incidence of stereopsis after treatment of infantile esotropia with botulinum toxin A. J Pediatr Ophthalmol Strabismus. 2003;40: 288-292.
77. Ruiz MF, Moreno M, Sanchez-Garrido CM, et al. Botulinum treatment of infantile esotropia with abduction nystagmus. J Pediatr Ophthalmol Strabismus. 2000;37:196-205.
78. Dawson EL, Marshman WE, Adams GG. The role of botulinum toxin A in acute-onset esotropia. Ophthalmology. 1999;106:1727-1730.
79. Tejedor J, Rodriguez JM. Long-term outcome and predictor variables in the treatment of acquired esotropia with botulinum toxin. Invest Ophthalmol Vis Sci 2001;42: 2542-2546.
80. Spencer RF, Tucker MG, Choi RY, et al. Botulinum toxin management of childhood intermittent exotropia. Ophthalmology. 1997;104:1762-1767.
81. Biglan AW, Burnstine RA, Rogers GL, et al. Management of strabismus with botulinum A toxin. Ophthalmology. 1989;96:935-943.
82. Dawson EL, Marshman WE, Lee JP. Role of botulinum toxin A in surgically over-corrected exotropia. J AAPOS. 1999;3:269-271.
83. Lawson JM, Kousoulides L, Lee JP. Long-term results of botulinum toxin in consecutive and secondary exotropia: outcome in patients initially treated with botulinum toxin. J AAPOS. 1998;2:195-200.
84. McNeer KW. An investigation of the clinical use of botulinum toxin A as a postoperative adjustment procedure in the therapy of strabismus. J Pediatr Ophthalmol Strabismus. 1990;27:3-9.
85. Tejedor J, Rodriguez JM. Early retreatment of infantile esotropia: comparison of reoperation and botulinum toxin. Br J Ophthalmol. 1999;83:783-787.
86. Lee J, Page B, Lipton J. Treatment of strabismus after retinal detachment surgery with botulinum neurotoxin A. Eye. 1991;5:451-455.
87. Scott AB. Botulinum treatment of strabismus following retinal detachment surgery. Arch Ophthalmol. 1990;108:509-510.
88. Maurino V, Kwan A, Khoo BK, et al. Ocular motility disturbances after surgery for retinal detachment. J AAPOS. 1998;2:285-292.
89. Quah BL, Ling YL, Cheong PY, et al. A review of 5 years' experience in the use of botulinum toxin A in the treatment of sixth cranial nerve palsy at the Singapore National Eye Centre. Singapore Med J. 1999;40:405-409.
90. Petitto VB, Buckley EG. Use of botulinum toxin in strabismus after retinal detachment surgery. Ophthalmology. 1991;98:509-513.
91. Ozkan SB, Kir E, Dayanir V, et al. Botulinum toxin A in the treatment of adherence syndrome. Ophthalmic Surg Lasers Imaging. 2003;34:391-395.